Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9NUM4
UPID:
T106B_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NUM4; A4D108; Q53FL9; Q8N4L0
Background:
Transmembrane protein 106B (TMEM106B) plays a crucial role in neuronal health, mediating the transport and sorting of lysosomes within neurons. Its involvement in dendrite morphogenesis and maintenance, as well as its potential role as a molecular brake for lysosome transport, underscores its importance in cellular functioning.
Therapeutic significance:
TMEM106B's association with neurodegenerative diseases such as Frontotemporal dementia and Amyotrophic lateral sclerosis highlights its potential as a therapeutic target. Understanding TMEM106B's functions could pave the way for novel treatments for these debilitating conditions.